

Press Release

MonTa Biosciences Announces Start of Phase 1 Clinical Trial in Cancer Patients with the Immunotherapeutic Nanoparticle MBS8

Copenhagen, Denmark, April 22, 2021. MonTa Biosciences, a Danish clinical stage biotech company located in Copenhagen, today announced the first patient has been dosed with MonTa Biosciences MBS8 in a Phase I clinical trial. Patients with solid tumors are enrolled at two Danish hospitals in Copenhagen, Rigshospitalet and Herlev Hospital. 30-50 patients will be enrolled over the next 18 months.

MonTa Biosciences lead candidate MBS8 was administered intravenously to the first patient in the trial at Rigshospitalet in Copenhagen on Wednesday, April 21. The primary objective of the trial is to evaluate the safety of multiple escalating doses of MBS8 for patients with advanced solid tumours and to establish the maximum tolerated dose (MTD/recommended Phase 2 dose (RP2D)). The effects on biomarkers and objective tumor response in the patients will also be assessed.

MBS8 treatment is an innovative way to stimulate the immune system to help the body fight cancer. MBS8 is a nanoparticle that contains an immune stimulating compound called a TLR7 agonist that activate certain types of immune cells which are able to enter tumor tissue from the blood and kill tumor cells. After weeks of treatment MBS8 is also able to stimulate immune memory T-cells to recognize and eliminate cancer cells, which is of particular interest to cancer patients with metastatic disease, where there is a huge unmet medical need for better treatment.

MonTa Biosciences' CEO, Simon S Jensen said "We are very excited to have the first patient dosed with MBS8 and hope the drug will demonstrate to be safe for the patients, and even more important also have an impact on their cancer. With the new mode of action for MBS8, which has never been seen for any cancer drug before, we have high expectations to MBS8 and hope we already in this phase I will be able to help patients in need. It is quite rare to see drugs acting as monotherapy on the immune system as efficiently as MBS8, often cancer immunotherapy treatments are combined with other treatments to enhance their therapeutic activity."

About MonTa Biosciences

MonTa Biosciences is a clinical stage biotech company located in Copenhagen, Denmark, and work with a cancer immunotherapy nanoparticle called micelles, which incorporates a TLR7 agonist. Our lead candidate MBS8 has shown superior antitumor activity in mouse models of cancer, and a favorable safety profile.

The MBS8 micelles were developed at The Danish Technical University using a TLR7 agonist that stimulates the immune system. Further, MonTa Biosciences collaborates with the Nanotechnology Characterization Laboratory (NCL) on behalf of the National Cancer Institute (NCI), located in

Maryland, USA. The NCL initiative supports MonTa Biosciences in advancing MBS8 towards clinical trials and to characterize MBS8 in more detail to enhance the understanding of how the drug works.

MonTa Biosciences is privately owned and has recently raised a series A investment to complete its phase I study.

Read more about MonTa Biosciences [here](#)

For more information contact:

Simon Skjøde Jensen, CEO

E-mail: Simonjensen@montabiosciences.com

Mobile Phone [+45 51186306](tel:+4551186306)